IS20
IS20 is a Prokineticin receptor 1 (PKR1) agonist. IS20 diminishes Doxorubicin mediated apoptosis and ROS production by activating Akt or MAPK pathways. IS20 protects the heart against Doxorubicin-induced cardiovascular toxicity and improves the survival rate and cardiac function in mouse models. IS20 does not alter the cytotoxicity and antitumor activity of acute DOX treatment in breast cancer cells and MDA-MB-231 xenograft mouse models. IS20 can be used for cancers research[1].
Product Specifications
CAS Number
324561-95-7
UNSPSC
12352005
Target
Akt; Apoptosis; G Protein-coupled Receptor Kinase (GRK) ; p38 MAPK; Reactive Oxygen Species (ROS)
Related Pathways
Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Cardiovascular Disease
Smiles
O=C(C1=CC=CC=C1)N/C(C(NCC2=CC=CN=C2)=O)=C/C3=CC=C(C=C3)OC
Molecular Formula
C23H21N3O3
Molecular Weight
387.43
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD63 (MX-49.129.5), CF405S conjugate, 0.1mg/mL
Tyrosinase (T311), CF640R conjugate, 0.1mg/mL
CD50 (ICAM-3) (101-1D2), CF640R conjugate, 0.1mg/mL
